
On Tuesday, Medtronic Plc (NYSE:MDT) reported second-quarter earnings and announced key board appointments after Elliott Investment Management became the company's largest shareholder.
The company also unveiled its new Growth Committee, tasked with overseeing the evaluation and execution of strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business.